Home > Products > Pharmaceutical R&D Materials > Functional Building Blocks > 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide
4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide structure, CAS 915087-33-1

4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide

CAS Number915087-33-1

SynonymsMDV3100; MDV 3100; Enzalutamide; Enzalutamidum; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-me; Xtandi; UNII-93T0T9GKNU; Enzalutamida; MDV-3100

Molecular FormulaC21H16O2N4S1F4

Molecular Weight464.44

Purity98.00%

Density1.5±0.1 g/cm3

Boiling Point

Melting Point

Flash Point

Appearance

EINECS

MSDSChineseEnglish

Symbol

Signal Word

Cat. No.: 2A-9059107 Purity: 98.00%
Change View

Please Login or Create an Account to: See VlP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

Quality Control of [ 915087-33-1 ] Purity: 98.00% SDS Specification MoL

Chemical & Physical Properties
CAS Number915087-33-1
Catalog No.2A-9059107
Chinese Name恩杂鲁胺
SynonymsMDV3100; MDV 3100; Enzalutamide; Enzalutamidum; 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-me; Xtandi; UNII-93T0T9GKNU; Enzalutamida; MDV-3100
Molecular FormulaC21H16O2N4S1F4
Molecular Weight464.44
Purity98.00
Density1.5±0.1 g/cm3
Storage Conditionroom temperature, dry
ApplicationEnzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 value of 36 nM for AR inhibition in LNCaP prostate cells.
HTC2933990090
MDL NumberMFCD14155804
SMILESCNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F
InChI KeyWXCXUHSOUPDCQV-UHFFFAOYSA-N
MSDSmsds/59107_1_915087_33_1.pdf
Use ofEnzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Properties Name enzalutamide Synonym More Synonyms Enzalutamide (MDV3100) Biological Activity Description Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Related Catalog Signaling Pathways >> Others >> Androgen Receptor Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Cancer IC50: 36 nM (androgen-receptor, in LNCaP cells)[1] References [1]. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790. [2]. Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375(9724), 1437-1446. [3]. Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73(12):1291-305. [4]. Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38(11):2076-82. Chemical & Physical Properties Molecular Formula C21H16F4N4O2S Exact Mass 464.093018 PSA 108.53000 Index of Refraction 1.630 InChIKey WXCXUHSOUPDCQV-UHFFFAOYSA-N Safety Information Hazard Codes Xi HS Code 2933990090 Synthetic Route 4-[(2-Cyanoprop... CAS#:915087-32-0 3-Fluoro-4-meth... CAS#:143782-23-4 Enzalutamide (M... CAS#:915087-33-1 N-[3-Fluoro-4-[... CAS#:1332524-01-2 3-Fluoro-4-meth... CAS#:143782-23-4 Enzalutamide (M... CAS#:915087-33-1 Thiophosgene CAS#:463-71-8 4-[1-(4-cyano-3... CAS#:1289942-55-7 Enzalutamide (M... CAS#:915087-33-1 Precursor & DownStream Precursor 9 CAS#:915087-32-0 4-[(2-Cyanoprop... CAS#:143782-23-4 3-Fluoro-4-meth... CAS#:1332524-01-2 N-[3-Fluoro-4-[... CAS#:463-71-8 Thiophosgene DownStream 0
Tax Rebate13.0%
SupervisionNone. MFN tariff: 6.5%. Ordinary tariff: 20.0%
Transport InfoProduct name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Contact Us

Phone:

630-322-8886

630-322-8887

Email:

[email protected]

Office Locations:

Chicago, IL, USA

San Francisco, CA, USA